Huma Therapeutics Acquires Alcedis GmbH

Huma Therapeutics Acquires Aluna with Strategic Investment from Eckuity Capital

May 16, 2025

Healthcare Services

Huma Therapeutics has acquired Aluna (also known as Knox Medical Diagnostics, Inc.) and announced a partnership and growth investment from Eckuity Capital to accelerate M&A. The acquisition adds Aluna’s remote respiratory monitoring devices and platform — including FDA-cleared spirometers and a clinician portal — to Huma’s Cloud Platform, expanding Huma’s respiratory capabilities and customer reach across 150+ U.S. health systems.

Kymanox Acquires anteris medical GmbH and anteris helvetia AG

February 2, 2023

Professional Services

Kymanox Corporation has acquired anteris medical GmbH (Germany) and anteris helvetia AG (Switzerland) to expand its European footprint and broaden its life-science professional services capabilities. The deal brings additional regulatory, quality, and combination-product expertise to Kymanox; terms were not disclosed.

ClariMed Acquires We Are Human

August 12, 2025

Medical Devices

ClariMed, a human-centered medical device development and regulatory services firm, has acquired We Are Human, a UK/US consultancy specializing in human factors, UX research, and usability testing. The deal brings We Are Human’s team and an Atlanta-based research lab into ClariMed, expanding the buyer’s capabilities and establishing its first Southeast U.S. location.

ACL Digital Acquires Symbiance

September 26, 2025

Healthcare Services

ACL Digital, an ALTEN Group company, has acquired Symbiance, a US-based contract research organization (CRO) that provides clinical data management, biostatistics, medical writing and pharmacovigilance services. The acquisition expands ACL Digital's life sciences capabilities by adding AI-driven clinical research, CRO and pharmacovigilance expertise to its digital transformation and engineering services.

Johnson & Johnson Acquires Halda Therapeutics for $3.05 Billion

December 29, 2025

Biotechnology

Johnson & Johnson completed the acquisition of Halda Therapeutics OpCo, Inc. for $3.05 billion in cash, adding Halda's RIPTAC platform and clinical-stage prostate cancer candidate HLD-0915 to its oncology portfolio. The deal brings several earlier-stage RIPTAC-based programs for other solid tumors and positions J&J to advance oral targeted therapies that may overcome treatment resistance.

Kymanox Acquires Agilis Consulting Group

March 24, 2023

Healthcare Services

Kymanox, a PE-backed life sciences professional services firm, has acquired Agilis Consulting Group, a Cincinnati-based human factors and usability engineering consultancy. The transaction (terms undisclosed) expands Kymanox's human factors, regulatory strategy, and usability engineering capabilities to support medical device, combination product, and biologics clients globally.